Navigation Links
Panel's Rejection of PSA Test Spurs Mixed Reaction From Experts
Date:10/8/2011

By Steven Reinberg
HealthDay Reporter

FRIDAY, Oct. 7 (HealthDay News) -- News that a key government advisory panel will give a thumbs-down next week to a controversial blood test for prostate cancer is garnering both praise and condemnation from experts.

A draft report due out early next week from the United States Preventive Services Task Force (USPSTF) will recommend that healthy men forego regular prostate-specific antigen (PSA) testing aimed at spotting prostate cancer, the The New York Times and other media outlets reported Friday.

The USPSTF is the same independent group of medical experts that caused a firestorm in late 2009 when they ruled against the use of annual mammographies for average-risk women in their 40s.

The PSA test has been similarly controversial, since its overall benefit in saving mens' lives has been challenged by a number of studies. Among the reasons the USPSTF cited in rejecting the PSA test is that the screen does not save lives and instead can result in unnecessary treatments that can leave men with discomfort, impotence and incontinence.

According to the Times, the task force focused on the results of five trials, the two largest done in Europe and in the United States. The European trial included 182,000 men. Over nine years of follow-up, it found no reduction in deaths due to prostate cancer among men of all ages in the study who were underwent PSA testing. But it did find some reduction in deaths among men aged 55 to 69 who got the blood test.

The American trial, involving almost 77,000 men followed for over a decade, also failed to show an overall reduction in deaths among all the men who were screened.

"Unfortunately, the evidence now shows that this test does not save men's lives," Dr. Virginia Moyer, a professor of pediatrics at Baylor College of Medicine and chairwoman of the task force, told the Times. "This test cannot tell the diffe
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. All Global Launches Physician Panels in Russia and Poland
2. ANY LAB TEST NOW Launches New Infectious Disease Panels - Affordable Panels Test for H1N1, Staph, E. coli and Other Infectious Diseases
3. FDA Panels to Weigh Dosing Labels for Kids OTC Fever Relievers
4. Astellas Responds to OSI Pharmaceuticals Rejection
5. Gene pattern may identify kidney transplant recipients who dont need life-long anti-rejection drugs
6. Gene pattern may identify kidney transplant recipients who dont need lifelong anti-rejection drugs
7. Study links romantic rejection with reward and addiction centers in the brain
8. Vitamin D deficiency linked to lung transplant rejection
9. UCLA team uncovers mechanism behind organ transplant rejection
10. Gift-Giving, for Many Men, Means Avoiding Rejection
11. Romantic Rejection May Hurt Just Like Physical Pain
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Panel's Rejection of  PSA Test Spurs Mixed Reaction From Experts
(Date:10/2/2014)... The Business Intelligence Group today ... for Business program. The BIG Awards specialize in ... judging process scored by well-known and experienced leaders ... winners this year epitomize what is going right ... the Business Intelligence Group. “The sheer amount of ...
(Date:10/2/2014)... By Maureen Salamon ... (HealthDay News) -- Middle-aged women with a neurotic personality ... of developing Alzheimer,s disease, new research suggests. Tracking ... that those who were most anxious, jealous and moody ... long-standing stress had double the risk of developing Alzheimer,s ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... may raise your risk for high blood pressure, a new ... who lived within 109 yards of a busy road had ... than women living at least half a mile away, researchers ... importance of our physical environment on our health and well-being," ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... the District of Columbia now have a total of 500 ... has been infecting children since the summer, U.S. health ... have died in recent weeks, but it,s not clear what ... deaths, officials said. Health officials are also trying to ...
(Date:10/1/2014)... scientists has shown that more than 80 per cent ... , The study found that medicines called ,JAK inhibitors, ... mutation that is present in more than 80 per ... used, or are in clinical trials, for diseases including ... Bowel cancer is the second-most common cancer in Australia ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... heart attack and stroke, U.S. officials say , , ... Prilosec with the popular blood thinner Plavix (clopidogrel) can ... at risk for heart attack or stroke, U.S. health ... recently submitted studies by the manufacturer of clopidogrel [Sanofi-Aventis ...
... Seattle Sutton,s Healthy Eating (SSHE) and the ... MCHC affiliated members with meal discounts for SSHE. , ... than 140 hospitals and health care organizations dedicated to improving ... care and in assisting its members in improving the delivery ...
... Mo. Until recently, scientists believed that, following a ... any lost function. After that, patients would be forced ... their remaining abilities. Although this belief has been refuted, ... the current health system is still not giving patients ...
... 17 As we approach Thanksgiving, "Black Friday" and the ... community to please remember the children and families whose lives ... recovery and survival. Among these diseases are leukemia and ... disease, hemophilia and other diseases. , Please take a few ...
... VEGAS, Nov. 17 Ultimat Vodka has recently announced plans ... eliminating world hunger, to help raise awareness and funds for ... "I,m Tired of...," (ITo) Ultimat has created unique wrist ... message "I,m Tired of Hunger." For each bracelet produced, Ultimat ...
... surgery, gunshot victim continues to show improvement , TUESDAY, ... the first facial transplant in the United States can ... her nose, according to a report from her surgeons. ... from the transplanted tissue have integrated with existing tissue, ...
Cached Medicine News:Health News:Heartburn Drugs Can Thwart Popular Blood Thinner 2Health News:Seattle Sutton's Healthy Eating Partners With Metropolitan Chicago Healthcare Council to Provide Discounts for Hospital Patients and Employees 2Health News:Seattle Sutton's Healthy Eating Partners With Metropolitan Chicago Healthcare Council to Provide Discounts for Hospital Patients and Employees 3Health News:Pushing the brain to find new pathways 2Health News:These Patients Need Your Help This Thanksgiving 2Health News:These Patients Need Your Help This Thanksgiving 3Health News:Ultimat Vodka Joins Fight Against Hunger 2Health News:Face Transplant Patient Can Smell, Taste, Breathe Normally 2Health News:Face Transplant Patient Can Smell, Taste, Breathe Normally 3
(Date:10/2/2014)... , Oct. 2, 2014  AxelaCare Health Solutions, ... services, announced today that it has acquired Advanced Care, ... intravenous therapy provider.  Terms of the transaction were not ... AxelaCare,s intravenous solutions pharmacies to 18 nationwide and expands ... New York - New Jersey ...
(Date:10/2/2014)... Intarcia Therapeutics, Inc. today announced successful top-line results ... for ITCA 650 (exenatide, delivered continuously once or twice ... trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical ... 650 in patients with type 2 diabetes against placebo. ... to placebo for both 40 mcg and 60 mcg ...
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014  Columbia ... that its subsidiary, Molecular Profiles Ltd., is set to ... annual CPhI/ICSE Worldwide event in Paris ... the rapid development of both standard and complex drug ... which incorporates the company,s existing formulation and analytical development ...
Breaking Medicine Technology:AxelaCare Health Solutions Acquires Advanced Care of New York 2AxelaCare Health Solutions Acquires Advanced Care of New York 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3
... Presented at the World Muscle Society International ... PTC Therapeutics, Inc.,(PTC), a biopharmaceutical company ... small-molecule drugs targeting,post-transcriptional control mechanisms, today announced ... of PTC124 in patients with Duchenne muscular,dystrophy ...
... Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) ... clinical and preclinical data on its lead ... the American Association for,Cancer Research (AACR), National ... and Treatment of Cancer (EORTC) entitled,"International Conference ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: